Janice Tsang, MBBS, MRCP(UK), FRCP (Lond.)
Specialist in Medical Oncology
Hon. Clinical Assistant Professor
Li Ka Sing Faculty of Medicine
The University of Hong Kong
How is hybrid-based NGS leading to improved stratification of patients with breast cancer?
How is hybrid-based NGS leading to improved stratification of patients with breast cancer?
What is the role of NGS for identifying “HER-2 enrichment” therapy? What is the situation in Asia as far deploying NGS in patients with breast cancer?
Can you provide an example of a luminal A patient with metastatic breast cancer in whom treatment was optimized by NGS-based, comprehensive genomic assessment?
How will hybrid capture-based NGS improve identification of patients with breast cancer who will benefit from trastuzumab therapy?
What is the role of hybrid capture-based NGS — full exome sequencing — for identifying targeted therapies in the setting of orphan cancers such as sarcoma? Can you cite some specific patient examples where NGS can offer actionable insights ...
What is the role of NGS in patients with triple-negative breast cancer? Is it controversial? Are there actionable insights than emerge from full exome sequencing in patients with TNBC who have progressed on standard therapies?
Why is there a growing reliance among precision oncology specialists on full exome sequencing with NGS — such as that provided by FoundationOne Medicine — as opposed to targeted, hotspot panels? What critical information does the report provide?